Researchers sought to compare the effect of abelacimab vs rivaroxaban on risk for bleeding in patients with atrial fibrillation.

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.

But at least from a medical perspective, it doesn't really matter. The vaccine is highly effective at preventing severe cases of shingles, and it seems to significantly reduce the frequency of ...

"A fecal immunochemical test-based colorectal cancer screening program was better accepted by participants than a screening ...

coronary revascularisation or hospitalisation for unstable angina – with a 25% relative risk reduction and a 4.8% absolute risk reduction in the first occurrence of major adverse cardiovascular ...

This corresponds to an absolute risk difference of −4.2% ... lowering HCC risk by 36% (aSHR 0.64), compared with a 21% risk reduction observed with hydrophilic statins such as rosuvastatin ...

That’s a 14% absolute risk reduction, which is fairly impressive.” Despite several caveats, “it’s hard to look at this trial as anything except a powerful and — to me, at least ...